A study to find the best dose of BI 836880 alone and in combination with BI 754091 in Japanese patients with different types of advanced cancer
Phase 1
Completed
- Conditions
- advanced solid tumours
- Registration Number
- JPRN-jRCT2080224681
- Lead Sponsor
- ippon Boehringer Ingelheim Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
1. Signed and dated written informed consent in accordance with International Council on Harmonisation (ICH) Good Clinical Practice (GCP) and local legislation prior to admission to the trial.
2. Patients with a confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours (any type).
Exclusion Criteria
1. Known hypersensitivity to the trial drugs or their excipients
2. Known HIV, HBV, or HCV infection
3. History of severe hypersensitivity reactions to other mAbs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method